Christian Augsberger

Planegg, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.

Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.

Journal: Haematologica
Published: December 29, 2023

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.

Journal: Frontiers in immunology
Published: May 10, 2023

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.

Journal: Blood
Published: November 03, 2022

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.

Journal: Journal of hematology & oncology
Published: March 05, 2021

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.

Journal: Blood
Published: December 22, 2020

A modular and controllable T cell therapy platform for acute myeloid leukemia.

A modular and controllable T cell therapy platform for acute myeloid leukemia.

Journal: Leukemia
Published: June 17, 2020

Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.

Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.

Journal: Clinical & translational immunology
Published: November 25, 2019

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.

Journal: Leukemia
Published: December 24, 2017

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.

Journal: Frontiers in immunology
Published: October 08, 2017
Showing 1-9 of 9

Last Updated: 09/26/2026